Analysts think VKTX stock price could increase by 360%
Apr 06, 2025, 11:25 AM
30.52%
What does VKTX do
Viking Therapeutics, based in San Diego, develops therapies for metabolic and endocrine disorders, including VK2809 for NASH, VK0214 for X-ALD, and VK2735 for metabolic issues. The company went public on April 29, 2015, and has 28 employees.
16 analysts think VKTX stock price will increase by 359.85%. The current median analyst target is $104.04 compared to a current stock price of $22.63. The lowest analysts target is $38.38 and the highest analyst target is $172.20.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
